MAP2K7 and neoplasm: While MEK inhibition may be demonstrated to be a successful therapeutic approach for cNF, the development of new cNF trials is partially dependent on the identification of novel and pharmacologically tractable molecular targets with critical relevance to NF1 tumour biology.